Claudin 18.2 靶向:泛癌视角
Claudin 18.2 Targeting: A Pan-Cancer Perspective.
FDA 对 zolbetuximab 批准的 CLDN18.2 阈值为 ≥ 75% 中度至强染色。
英文原题:Tumor-Infiltrating Lymphocytes Demonstrate Distinct Behavior in the Tumoral and Peritumoral Microenvironment After Neoadjuvant Chemotherapy in Patients with Resected Adenocarcinoma of the Gastric or Gastroesophageal Junction: Results from a Single Center.
结果:共回顾了106例患者。
背景/目的:食管胃和胃腺癌通常采用包括新辅助化疗和手术在内的多模式治疗。新辅助化疗对宿主抗肿瘤免疫反应的影响在很大程度上仍不清楚。方法:回顾性分析单中心队列中接受新辅助化疗FLOT(氟尿嘧啶、亚叶酸、奥沙利铂、多西他赛)后行根治性意向手术的胃或食管胃腺癌患者。经机构伦理批准后,重新审阅病理切片并计算TIL(肿瘤浸润淋巴细胞)评分。TIL(肿瘤浸润淋巴细胞)(TILs)与肿瘤消退评分(TRG)、受累淋巴结的消退程度以及淋巴结比率(受累淋巴结数与切除淋巴结总数之比)进行联合研究。结果:共回顾了106例患者。TIL(肿瘤浸润淋巴细胞)评分与原发肿瘤的消退程度以及病理受累淋巴结对化疗的部分反应之间未能建立统计学相关性。在我们的患者队列中,TIL评分也与淋巴结比率无关。观察到TILs与新辅助化疗后完全消退的淋巴结之间存在强相关性。结论:TIL(肿瘤浸润淋巴细胞)与原发肿瘤的反应或受累淋巴结的部分反应无关,仅与肿瘤受累淋巴结对新辅助化疗的完全反应相关。我们的研究关注新辅助化疗对TIL(肿瘤浸润淋巴细胞)的影响,并与对原发肿瘤及受累淋巴结的影响进行比较。
Background/Objectives : Adenocarcinomas of the esophagogastric and gastric areas are often managed with a multimodal treatment including neoadjuvant chemotherapy and surgery. The impact of neoadjuvant chemotherapy on the host's antitumoral immune response remains largely unknown. Methods : A retrospective review of a single-institution cohort of patients with adenocarcinoma of the stomach or esophagogastric area undergoing curative intent surgery after neoadjuvant chemotherapy FLOT (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) was reviewed. After institutional ethics approval, pathologic slides were re-reviewed and tumor-infiltrating lymphocyte scores were calculated. Tumor-infiltrating lymphocytes (TILs) were studied in conjunction with tumor regression scores (TRG) and the degree of regression in the involved lymph nodes as well as in correlation with the lymph node ratio (the ratio of involved lymph nodes over the total number of lymph nodes resected). Results : A total of 106 patients were reviewed. No statistical correlation could be established between the tumor-infiltrating lymphocyte scores and the degree of regression in the primary tumor as well as with the partial response to chemotherapy of pathologically involved lymph nodes. The TIL score also did not correlate with the lymph node ratio in our patient cohort. A strong correlation was noted between TILs and lymph nodes that completely regressed after neoadjuvant chemotherapy. Conclusions : Tumor-infiltrating lymphocytes do not correlate with the response of the primary tumor or the partial response of the involved lymph nodes, but only with the complete response to neoadjuvant chemotherapy of tumor-involved lymph nodes. Our study focuses on the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes compared to the effects on the primary tumor and the involved lymph nodes.
MEMBER ACCOUNT
登录成功会直接打开下一页。